Frederique Ph.D. Menzaghi - 01 Feb 2024 Form 4 Insider Report for Cara Therapeutics, Inc. (TVRD)

Reporting relationship: CHIEF SCIENTIFIC OFF,SVP-R&D
Issuer ticker: TVRD
Reported as of: 01 Feb 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Feb 2024, 16:28:07 UTC
Prior SEC filing: 27 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Darren DeStefano, Attorney-in-Fact

Key filing fact

Frederique Ph.D. Menzaghi filed Form 4 for Cara Therapeutics, Inc. (TVRD) on 05 Feb 2024.

Key facts

This page summarizes Frederique Ph.D. Menzaghi's Form 4 filing for Cara Therapeutics, Inc. (TVRD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Feb 2024, 16:28.

Change

Previous filing in this sequence was filed on 27 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CARA transaction

Common Stock

Award

Transaction value: $0
Shares: +13,500
Change %: +8.8%
Price: $0.000000
Shares after: 167,247
Date: 01 Feb 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Frederique Ph.D. Menzaghi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.